ASSESSMENT OF COGNITIVE AND BRAIN METABOLIC CHANGES IN RESPONSE TO IAS TREATMENT

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Prostate cancer is the most common form of cancer diagnosed in men. Intermittent androgen suppression (IAS) is a common treatment strategy for men diagnosed with prostate cancer that cycles androgen withdrawal (6-9 months) with an "off treatment" period allowing testosterone levels to return to physiological levels. Treatment is then reinstated as the prostate specific antigen (PSA) reaches a threshold dependent upon primary therapy. The proposed study examines changes in mood, cognition, brain metabolism, and Abeta levels in men with non-metastatic prostate cancer undergoing IAS treatment and healthy men, and will use both behavioral and brain metabolic methods to assess change. We will also examine APOE status as a possible modulating factor for cognitive changes